Phase II Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers
Status:
Not yet recruiting
Trial end date:
2028-12-01
Target enrollment:
Participant gender:
Summary
This study is an open-label, phase II study with a safety lead-in to assess the response rate
of induction olaparib and stereotactic beam radiotherapy (SBRT) followed by combination
olaparib/pembrolizumab in patients with metastatic gastric and GEJ cancers after at least one
of therapy.